Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 10
  1. Jun 05, 2026 · 16:01 · GREY · Routine +

    Grey Matters Health Secures $500K Tranche as Florida Neuroimaging Clinics Edge Closer to Opening

    Grey Matters Closes First Tranche of $500,000 of its Private Placement Financing

    01
  2. Jun 05, 2026 · 10:00 · ADK · Routine +

    DIAGNOS Inc. Awaits Health Canada Catalyst as Cash Runway Narrows Ahead of Dilutive Financing

    Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform

    02
  3. Jun 05, 2026 · 08:31 · DTR · Routine +

    DiagnosTear’s TeaRx Validation Fails to Halt 65% Decline as CLARIFY Royalties Weigh on Near-Term Upside

    DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal

    03
  4. Jun 05, 2026 · 08:30 · SEGN · Routine −

    Seegnal Inc. - AI-Driven Prescription Intelligence Platform for Medication Safety

    Seegnal Accepted into Innovative Accelerator Program from AARP, the Largest U.S. Organization Serving Americans 50 and Older

    04
  5. Jun 04, 2026 · 18:11 · AJA · Routine +

    Aja Health and Wellness Inc. Sells GOeVisit Telehealth Assets for $1.15M CAD to Focus on Core Growth Initiatives

    Aja Health and Wellness Inc. Announces Agreement for the Sale of Assets of GOeVisit Service

    05
  6. Jun 04, 2026 · 11:12 · MBIO · Routine +

    MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

    MindBio Launches Intox AI(TM) in Major Advancement for Drug Use Detection

    06
  7. Jun 04, 2026 · 07:41 · ARCH · Routine +

    Arch Biopartners Advances Dual AKI Pipeline Amid Steady Cash Burn and Dilutive Financing

    Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

    07
  8. Jun 04, 2026 · 07:01 · VIVI · Routine +

    TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

    TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

    08
  9. Jun 04, 2026 · 07:00 · ALGO · Routine +

    Light AI Advances FDA Pivotal Trial for Strep A AI Diagnostic Amid Cash Burn and Dilutive Financing

    LIGHT AI ANNOUNCES INITIATION OF FDA PIVOTAL CLINICAL TRIAL FOR QUICKSCAN(TM) STREP A SOFTWARE AS A MEDICAL DEVICE (SaMD)

    09
  10. Jun 04, 2026 · 07:00 · EDT · Routine +

    Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial

    Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial

    10
  11. Jun 03, 2026 · 18:18 · PTEC · Neutral

    Principal Technologies Steps Up Capital Raise to $0.50 to Clear Debt and Fund Oxford Thermal Sensor Development

    PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING AND DEBT SETTLEMENT TRANSACTIONS

    11
  12. Jun 03, 2026 · 18:07 · CTX · Routine +

    Crescita Therapeutics Closes $0.80 All-Cash Acquisition by ClinActiv, Delisting TSX and Cashing Out Shareholders

    Crescita Therapeutics Inc. Announces Closing of Arrangement

    12
  13. Jun 03, 2026 · 15:13 · METX · Routine −

    ME Therapeutics raises $500K via private placement to fund R&D and pursue U.S. listing as stock trades near 52-week lows.

    ME Therapeutics Announces Private Placement

    13
  14. Jun 03, 2026 · 07:00 · MDNA · Neutral

    ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

    Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

    14
← Newer Older →